Slide 1: Q1 2025 results
Q1 2025 results D Portfolio continues to deliver Conference call and webcast for analysts and investors 29 April 2025
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains certain forward-looking statements with respect to certain of the Company’s current expectations and projections about future events. These statements, which sometimes use words such as “intend,” “proposed,” “plan,” “expect,” and words of similar
Slide 3: Conference call agenda
Conference call agenda Business update Guido Oelkers, Chief Executive Officer Financials Henrik Stenqvist, Chief Financial Officer R&D Pipeline Lydia Abad-Franch, Head of R&D and Chief Medical Officer Summary and Q&A 3
Slide 4: Positive progress in our strategic portfolio
Positive progress in our strategic portfolio Overall Portfolio grew 23% at CER (exc RSV & final ReFacto revenue) Q1 growth impacted by last ReFacto manufacturing revenue and last strong sales of Synagis in Q1 2024 Revenue Q1: SEK 6,465 M, +3% Adjusted EBITA margin Q1: 36% Portfolio grew +23% excludi
Slide 5: Solid growth trajectory in the first quarter
Solid growth trajectory in the first quarter Driven by existing and launch medicines and continued growth geographically Revenue by segment Revenue by region Q1 2025 change contrib. Q1 2025 change SEK M % % SEK M % Haematology 4,632 +13 72 Europe 2,518 +19 – Haemophilia 2,823 +3 44 North America 2,1
Slide 6: Strong momentum across the portfolio in Q1
Strong momentum across the portfolio in Q1 First quarter 2025 Haematology • Haemophilia A: Growing 29 % driven by robust Altuvoct Elocta 1,272 -5% launch Altuvoct 455 >200% Alprolix 581 -5% • Doptelet: Continued strong demand across all markets Altuviiio royalty 220 +9% with 47 % growth Other Haem r
Slide 7: Altuvoct: Strong launch success in Germany & Switzerland
Altuvoct: Strong launch success in Germany & Switzerland Continuous initial sales progress across Europe & Middle East Achieved 57% share in prophylactic factor market in Haemophilia A in Germany since launch Haemophilia A sales SEK 1,727 M +29% Q1 Altuvoct launch: • First quarter 2025 sales of SEK
Slide 8: Aspaveli: Best-in-class Phase 3 efficacy data, on track for EU nephrology launch in 2026
Aspaveli: Best-in-class Phase 3 efficacy data, on track for EU nephrology launch in 2026 Aspaveli/Empaveli SEK 333 M +39% Q1 PNH • Continued growth across markets, Q1 2025 SEK 333 M, growth 39% at CER • Perseverance in markets with new competition Nephrology*: EU filing in Q1, CHMP opinion expected
Slide 9: Vonjo: Stable demand but sales impact in Q1
Vonjo: Stable demand but sales impact in Q1 Vonjo SEK 306 M -6% Q1 • Three quarters of consecutive growth followed by consolidation in Q1 • Demand volume stable quarter over quarter • Patient share remains consistent with overall share ~10% • Underlying revenue growth impacted by stocking and higher
Slide 10: Vonjo: Our strategy to unlocking the full potential
Vonjo: Our strategy to unlocking the full potential Status Take share in the US MF market • Continue to grow in <50K label population • Growth in (50-100K platelet population) in line with NCCN guidelines* • Generate more data to potentially expand label and complete full approval Expand Internation
Slide 11: Beyfortus: US RSV revenue following established seasonal vaccine patterns
Beyfortus: US RSV revenue following established seasonal vaccine patterns RSV seasonal revenue SEK 2,963 M Beyfortus royalties • Strong full season in US with high demand in Q3/Q4 1,600 • Royalties in Q1 SEK 189 M 1,400 Synagis 1,200 1,000 • Revenue Q1 SEK 21 M 800 RSV franchise: 2024/25 season 600
Slide 12: Gamifant; Kineret: Sustained strong performance
Gamifant; Kineret: Sustained strong performance Immunology revenue +22% at CER (exc seasonal RSV revenue) Gamifant Kineret SEK 582 M SEK 735 M +31% Q1 +16% Q1 Sales in SEK M at actual exchange rates; change at constant exchange rates. 12
Slide 13: Sobi's near term building block of the future
Sobi’s near term building block of the future Investment in 2025 for multiple launches in 2025/26 2 3 4 Major launches Key filing Priority development projects in area of high 1. Altuvoct 1. Gamifant - HLH/MAS unmet medical need 2. Vonjo 2. Aspaveli - C3G/IC- MPGN 1. Gamifant - IDS 3. NASP - uncontr
Slide 14: Agenda
Agenda Business update Guido Oelkers, Chief Executive Officer Financials Henrik Stenqvist, Chief Financial Officer R&D Pipeline Lydia Abad-Franch, Head of R&D and Chief Medical Officer Summary and Q&A 14
Slide 15: Q1 2025 Revenue and profit & loss
Q1 2025 Revenue and profit & loss Q1 Q1 Full-year Total revenue (SEK M) Amounts in SEK M 2025 2024 Change 2024 Haematology Immunology Specialty Care Total revenue 6,465 6,256 3% 26,027 Adjusted Gross profit 1,2 4,968 4,735 5% 20,326 7 436 6 894 385 Adjusted Gross margin 1,2 77% 76% 78% 6 256 311 6 4
Slide 16: Sobi Outlook 2025
Sobi Outlook 2025 Key considerations for 2025 2025 outlook • Altuvoct launch progress Revenue • Continued progress with commercial portfolio Anticipated to grow by a high single- • Beyfortus royalty digit percentage at CER • Launch preparation • In US for NASP in uncontrolled gout • In Europe for As
Slide 17: P&L currency exposure - illustrative
P&L currency exposure - illustrative 100% Illustration of how FX movements affect Sobi P&L • Revenue nearly a 1:1 impact as almost all our revenue is derived in non-SEK currencies 50% • COGS and OPEX: Approx 15-20% of COGS and OPEX is in SEK • EBITA margin: Relatively protected due to currency mix o
Slide 18: Agenda
Agenda Business update Guido Oelkers, Chief Executive Officer Financials Henrik Stenqvist, Chief Financial Officer R&D Pipeline Lydia Abad-Franch, Head of R&D and Chief Medical Officer Summary and Q&A 18
Slide 19: Solid pipeline progress in Q1 2025
Solid pipeline progress in Q1 2025 C3G and IC-MPGN Aspaveli/Empaveli EMA application successfully submitted HLH/MAS in Still’s disease Gamifant FDA priority review granted Interferon-γ driven sepsis (IDS) First patient enrolled in PoC study1 Synovitis SHINE Altuvoct First patient enrolled in Phase 4
Slide 20: Emapalumab: Pioneering new ways of treating hyperinflammation in sepsis
Emapalumab: Pioneering new ways of treating hyperinflammation in sepsis Can emapalumab improve High unmet medical need in new sepsis endotype interferon-gamma driven sepsis (IDS) outcomes in interferon-gamma driven sepsis? EMBRACE4 – exploratory phase 2 Mortality study in IFNγ driven sepsis Accounts
Slide 21: Driving the paradigm shift toward normalised haemostasis in haemophilia
Driving the paradigm shift toward normalised haemostasis to address unmet needs in haemophilia Targeting non-haemophilia FVIII Synovitis: Can Altuvoct improve levels is becoming the new major and most common synovitis outcomes? treatment paradigm complication in haemophilia 12-month, interventional,
Slide 22: Progress to be continued in 2025
Progress to be continued in 2025 Anticipated major pipeline news flow Aspaveli NASP Gamifant CHMP opinion Finalising FDA FDA decision PMDA submission submission 2025 H1 2025 H2 Gamifant – HLH / MAS in Still’s disease Gamifant – HLH / MAS in Still’s disease o US regulatory decision o Japan regulatory
Slide 23: Agenda
Agenda Business update Guido Oelkers, Chief Executive Officer Financials Henrik Stenqvist, Chief Financial Officer R&D Pipeline Lydia Abad-Franch, Head of R&D and Chief Medical Officer Summary and Q&A 23
Slide 24: Summary: Growth and pipeline progress
Summary: Growth and pipeline progress % growth at CER Revenue : Q1 2025 - SEK 6,465 M, +3% Significant growth Third consecutive year as 23% at CER (exc RSV & final ReFacto revenue) member of DJSI Europe Doptelet SEK 1,129 M, +47% Altuvoct SEK 455 M >200% Strategic portfolio Aspaveli/Empaveli SEK 33
Slide 25: Q&A
Q&A 25
Slide 26: Current Development Pipeline
Current Development Pipeline Major ongoing clinical studies and medicines in registration in a major region or country Phase 2 Phase 3 Registration Aspaveli®(pegcetacoplan) Vonjo® (pacritinib) Aspaveli®(pegcetacoplan) Transplant-associated thrombotic Myelofibrosis with severe microangiopathy after a
Slide 27: Appendix: Q1 2025 sustainability performance
Appendix: Q1 2025 sustainability performance Highlights in Q1 2025 Sobi sustainability priorities Highlights in Q1 2025 • Milestones toward increased access Maintain commitment to Always act responsibly • Caring for employees - Approval by EMA of indication extension patients - Presented Sobi’s Rare
Slide 28: Thank you
CONFIDENTIAL – FOR INTERNAL USE ONLY Thank you Sobi is a trademark of Swedish Orphan Biovitrum AB (publ). © Swedish Orphan Biovitrum AB (publ) – All rights reserved Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm • Sweden www.sobi.com